Monika Anna Niewczas, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetic Nephropathies | 32 | 2024 | 973 | 3.630 |
Why?
|
Diabetes Mellitus, Type 1 | 28 | 2021 | 3447 | 1.990 |
Why?
|
Kidney Failure, Chronic | 17 | 2024 | 2496 | 1.950 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 9 | 2018 | 257 | 1.570 |
Why?
|
Albuminuria | 16 | 2021 | 658 | 1.230 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 6 | 2016 | 348 | 1.100 |
Why?
|
Glomerular Filtration Rate | 19 | 2020 | 2227 | 0.730 |
Why?
|
Fatty Acids, Volatile | 1 | 2021 | 100 | 0.710 |
Why?
|
Diabetes Mellitus, Type 2 | 15 | 2022 | 12252 | 0.630 |
Why?
|
Kidney | 17 | 2023 | 7065 | 0.610 |
Why?
|
Metabolomics | 7 | 2022 | 1674 | 0.530 |
Why?
|
Renal Insufficiency, Chronic | 4 | 2019 | 2298 | 0.490 |
Why?
|
Proteinuria | 6 | 2017 | 612 | 0.460 |
Why?
|
Amino Acids, Essential | 1 | 2014 | 26 | 0.450 |
Why?
|
Fatty Acids | 1 | 2021 | 1811 | 0.420 |
Why?
|
Uremia | 1 | 2014 | 202 | 0.410 |
Why?
|
Disease Progression | 23 | 2022 | 13665 | 0.380 |
Why?
|
Indians, North American | 1 | 2014 | 354 | 0.360 |
Why?
|
Immunoglobulins | 1 | 2012 | 854 | 0.310 |
Why?
|
Creatinine | 8 | 2018 | 1918 | 0.290 |
Why?
|
Fibroblast Growth Factors | 1 | 2013 | 873 | 0.280 |
Why?
|
Pyruvate Kinase | 2 | 2019 | 191 | 0.260 |
Why?
|
Interleukin-8 | 3 | 2021 | 704 | 0.230 |
Why?
|
Glutamate-Ammonia Ligase | 2 | 2015 | 76 | 0.230 |
Why?
|
Podocytes | 3 | 2021 | 404 | 0.220 |
Why?
|
Kidney Function Tests | 6 | 2017 | 684 | 0.220 |
Why?
|
Blood Proteins | 3 | 2024 | 1191 | 0.220 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2019 | 4351 | 0.210 |
Why?
|
Matrix Metalloproteinase 7 | 1 | 2023 | 60 | 0.210 |
Why?
|
Cathepsin B | 1 | 2002 | 80 | 0.200 |
Why?
|
Fibrinolysin | 1 | 2002 | 130 | 0.200 |
Why?
|
Collagenases | 1 | 2002 | 221 | 0.190 |
Why?
|
Trypsin | 1 | 2002 | 491 | 0.190 |
Why?
|
Nephritis, Interstitial | 1 | 2002 | 157 | 0.190 |
Why?
|
Cathepsins | 1 | 2002 | 243 | 0.190 |
Why?
|
Receptors, CXCR | 1 | 2021 | 52 | 0.190 |
Why?
|
Diabetes Mellitus, Experimental | 3 | 2022 | 1124 | 0.180 |
Why?
|
Alginates | 1 | 2022 | 250 | 0.180 |
Why?
|
Proteomics | 8 | 2024 | 3912 | 0.180 |
Why?
|
Glomerulonephritis | 1 | 2002 | 333 | 0.180 |
Why?
|
Risk Factors | 17 | 2022 | 74936 | 0.180 |
Why?
|
Receptors, Tumor Necrosis Factor | 2 | 2020 | 587 | 0.170 |
Why?
|
Adult | 40 | 2024 | 223583 | 0.170 |
Why?
|
Kidney Glomerulus | 3 | 2019 | 571 | 0.170 |
Why?
|
Liver Transplantation | 7 | 2003 | 2401 | 0.160 |
Why?
|
Biomimetics | 1 | 2020 | 172 | 0.160 |
Why?
|
Multivariate Analysis | 5 | 2021 | 12075 | 0.160 |
Why?
|
Kidney Transplantation | 4 | 2017 | 4261 | 0.160 |
Why?
|
Middle Aged | 37 | 2024 | 223422 | 0.160 |
Why?
|
Proportional Hazards Models | 6 | 2019 | 12536 | 0.150 |
Why?
|
Cystatin C | 5 | 2013 | 272 | 0.150 |
Why?
|
Diabetic Foot | 1 | 2022 | 382 | 0.150 |
Why?
|
Male | 44 | 2024 | 364641 | 0.150 |
Why?
|
Enzymes | 1 | 2019 | 254 | 0.140 |
Why?
|
Female | 44 | 2024 | 397113 | 0.140 |
Why?
|
Uric Acid | 4 | 2013 | 805 | 0.130 |
Why?
|
Renal Insufficiency | 1 | 2022 | 812 | 0.130 |
Why?
|
Glucose | 2 | 2019 | 4351 | 0.130 |
Why?
|
Humans | 62 | 2024 | 767991 | 0.130 |
Why?
|
Interleukin-6 | 3 | 2019 | 3228 | 0.130 |
Why?
|
Membrane Potential, Mitochondrial | 1 | 2017 | 297 | 0.130 |
Why?
|
Inflammation Mediators | 3 | 2019 | 1892 | 0.120 |
Why?
|
Antigens | 1 | 2020 | 1442 | 0.120 |
Why?
|
Chemokine CCL2 | 3 | 2018 | 605 | 0.110 |
Why?
|
Signal Transduction | 6 | 2024 | 23642 | 0.110 |
Why?
|
Endpoint Determination | 1 | 2017 | 592 | 0.110 |
Why?
|
Kidney Tubules, Proximal | 2 | 2013 | 386 | 0.110 |
Why?
|
Time Factors | 12 | 2021 | 40214 | 0.110 |
Why?
|
Coronary Disease | 2 | 2022 | 5919 | 0.110 |
Why?
|
Neuroblastoma | 1 | 2022 | 1266 | 0.110 |
Why?
|
Diabetes Mellitus | 3 | 2022 | 5887 | 0.110 |
Why?
|
Kininogen, High-Molecular-Weight | 1 | 2013 | 6 | 0.110 |
Why?
|
Purinergic P2X Receptor Antagonists | 1 | 2012 | 24 | 0.110 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2017 | 878 | 0.100 |
Why?
|
Apoptosis | 2 | 2024 | 9521 | 0.100 |
Why?
|
Receptors, Purinergic P2X7 | 1 | 2012 | 86 | 0.100 |
Why?
|
Follow-Up Studies | 12 | 2017 | 39345 | 0.100 |
Why?
|
Predictive Value of Tests | 5 | 2018 | 15442 | 0.100 |
Why?
|
Kidney Diseases | 3 | 2012 | 2100 | 0.090 |
Why?
|
Urine | 1 | 2013 | 362 | 0.090 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2013 | 640 | 0.090 |
Why?
|
Chemokine CXCL10 | 2 | 2010 | 311 | 0.090 |
Why?
|
Acetylglucosaminidase | 1 | 2010 | 66 | 0.090 |
Why?
|
Cell Cycle Proteins | 1 | 2022 | 3443 | 0.090 |
Why?
|
Graft Rejection | 4 | 2012 | 4492 | 0.090 |
Why?
|
Case-Control Studies | 7 | 2021 | 22287 | 0.090 |
Why?
|
Prognosis | 5 | 2019 | 29979 | 0.080 |
Why?
|
Cohort Studies | 6 | 2021 | 41749 | 0.080 |
Why?
|
Incidence | 6 | 2014 | 21532 | 0.080 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2002 | 2333 | 0.080 |
Why?
|
Mass Spectrometry | 2 | 2014 | 2202 | 0.080 |
Why?
|
Prospective Studies | 4 | 2022 | 54924 | 0.080 |
Why?
|
Hyperglycemia | 1 | 2018 | 1388 | 0.080 |
Why?
|
Tuberculosis | 1 | 2002 | 2029 | 0.080 |
Why?
|
Interleukin-10 | 1 | 2014 | 1183 | 0.080 |
Why?
|
Postoperative Complications | 5 | 2003 | 15831 | 0.080 |
Why?
|
Fas Ligand Protein | 1 | 2008 | 216 | 0.080 |
Why?
|
Islets of Langerhans | 1 | 2014 | 1351 | 0.070 |
Why?
|
Natural Killer T-Cells | 1 | 2011 | 318 | 0.070 |
Why?
|
MicroRNAs | 2 | 2021 | 3804 | 0.070 |
Why?
|
Risk | 2 | 2017 | 9609 | 0.070 |
Why?
|
Aged | 10 | 2024 | 171446 | 0.070 |
Why?
|
Glutamic Acid | 1 | 2013 | 1189 | 0.070 |
Why?
|
Coronary Vessels | 1 | 2019 | 3124 | 0.070 |
Why?
|
Mitochondria | 2 | 2019 | 3681 | 0.070 |
Why?
|
Immunosuppressive Agents | 4 | 2003 | 4205 | 0.070 |
Why?
|
Adenosine Triphosphate | 1 | 2012 | 2004 | 0.070 |
Why?
|
Liver Neoplasms | 1 | 2002 | 4362 | 0.070 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2008 | 693 | 0.070 |
Why?
|
Chromatography, Liquid | 3 | 2017 | 996 | 0.060 |
Why?
|
Fibrosis | 2 | 2023 | 2080 | 0.060 |
Why?
|
Immune Tolerance | 1 | 2014 | 2322 | 0.060 |
Why?
|
Intercellular Adhesion Molecule-1 | 1 | 2008 | 1134 | 0.060 |
Why?
|
Patient Selection | 1 | 2017 | 4258 | 0.060 |
Why?
|
Survival Rate | 5 | 2012 | 12828 | 0.060 |
Why?
|
Cytokines | 4 | 2011 | 7450 | 0.060 |
Why?
|
Transforming Growth Factor beta | 2 | 2022 | 1996 | 0.060 |
Why?
|
Cyclosporine | 2 | 2003 | 777 | 0.060 |
Why?
|
Metabolic Networks and Pathways | 2 | 2019 | 800 | 0.060 |
Why?
|
Forkhead Transcription Factors | 1 | 2011 | 1625 | 0.060 |
Why?
|
Boston | 2 | 2014 | 9368 | 0.050 |
Why?
|
Mice, Inbred NOD | 2 | 2020 | 1837 | 0.050 |
Why?
|
Longitudinal Studies | 3 | 2014 | 14783 | 0.050 |
Why?
|
T-Lymphocytes | 1 | 2020 | 10264 | 0.050 |
Why?
|
Tacrolimus | 2 | 2003 | 750 | 0.050 |
Why?
|
National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2022 | 26 | 0.050 |
Why?
|
Biliary Tract Diseases | 1 | 2003 | 159 | 0.050 |
Why?
|
Mice, SCID | 2 | 2020 | 2627 | 0.050 |
Why?
|
Cathepsin L | 1 | 2002 | 69 | 0.050 |
Why?
|
Fluorometry | 1 | 2002 | 99 | 0.050 |
Why?
|
Uridine | 1 | 2022 | 135 | 0.050 |
Why?
|
Endostatins | 1 | 2022 | 167 | 0.050 |
Why?
|
Receptors, Interleukin-8A | 1 | 2021 | 47 | 0.050 |
Why?
|
Receptors, Interleukin-8B | 1 | 2021 | 58 | 0.050 |
Why?
|
Mycophenolic Acid | 1 | 2003 | 348 | 0.050 |
Why?
|
Risk Assessment | 4 | 2018 | 24314 | 0.050 |
Why?
|
Cadaver | 2 | 2003 | 1363 | 0.050 |
Why?
|
Culture Media, Conditioned | 1 | 2022 | 521 | 0.050 |
Why?
|
Living Donors | 2 | 2003 | 647 | 0.040 |
Why?
|
Bandages | 1 | 2022 | 272 | 0.040 |
Why?
|
Peptide Fragments | 1 | 2013 | 5151 | 0.040 |
Why?
|
Gene Expression Profiling | 2 | 2013 | 9536 | 0.040 |
Why?
|
Animals | 9 | 2022 | 169222 | 0.040 |
Why?
|
Massachusetts | 1 | 2013 | 8888 | 0.040 |
Why?
|
Membrane Glycoproteins | 1 | 2010 | 3710 | 0.040 |
Why?
|
Peptide Hydrolases | 1 | 2002 | 610 | 0.040 |
Why?
|
Cysteine Endopeptidases | 1 | 2002 | 542 | 0.040 |
Why?
|
Italy | 1 | 2021 | 856 | 0.040 |
Why?
|
Heart Transplantation | 1 | 2012 | 3301 | 0.040 |
Why?
|
Lectins, C-Type | 1 | 2022 | 594 | 0.040 |
Why?
|
Mice | 7 | 2022 | 82024 | 0.040 |
Why?
|
Tandem Mass Spectrometry | 2 | 2017 | 1197 | 0.040 |
Why?
|
Cystatins | 2 | 2008 | 55 | 0.040 |
Why?
|
Extracellular Matrix Proteins | 1 | 2002 | 832 | 0.040 |
Why?
|
Polymorphism, Single Nucleotide | 2 | 2015 | 16041 | 0.040 |
Why?
|
Liver Function Tests | 3 | 2003 | 526 | 0.040 |
Why?
|
Focal Adhesions | 1 | 2018 | 113 | 0.040 |
Why?
|
Necrosis | 1 | 2002 | 1616 | 0.040 |
Why?
|
Mice, Inbred C57BL | 4 | 2021 | 22381 | 0.040 |
Why?
|
Models, Biological | 1 | 2013 | 9493 | 0.040 |
Why?
|
Telomere-Binding Proteins | 1 | 2018 | 122 | 0.040 |
Why?
|
Th1 Cells | 2 | 2012 | 1042 | 0.030 |
Why?
|
Cytomegalovirus Infections | 1 | 2003 | 836 | 0.030 |
Why?
|
C-Reactive Protein | 1 | 2008 | 3858 | 0.030 |
Why?
|
Retrospective Studies | 11 | 2012 | 81746 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2022 | 15660 | 0.030 |
Why?
|
Cell Line | 3 | 2017 | 15597 | 0.030 |
Why?
|
Cells, Cultured | 3 | 2021 | 19017 | 0.030 |
Why?
|
Lymphocyte Activation | 2 | 2020 | 5505 | 0.030 |
Why?
|
Tissue Donors | 2 | 2003 | 2381 | 0.030 |
Why?
|
Mice, Transgenic | 2 | 2021 | 9556 | 0.030 |
Why?
|
Autopsy | 1 | 2019 | 1011 | 0.030 |
Why?
|
Epidermal Growth Factor | 1 | 2018 | 697 | 0.030 |
Why?
|
Nerve Growth Factors | 1 | 2018 | 564 | 0.030 |
Why?
|
Reoperation | 2 | 2003 | 4329 | 0.030 |
Why?
|
Recombinant Fusion Proteins | 1 | 2003 | 3740 | 0.030 |
Why?
|
Young Adult | 3 | 2017 | 60048 | 0.030 |
Why?
|
Adrenal Cortex Hormones | 1 | 2003 | 1883 | 0.030 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2017 | 706 | 0.030 |
Why?
|
Pancreas | 1 | 2020 | 1700 | 0.030 |
Why?
|
United States | 3 | 2022 | 73027 | 0.030 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2020 | 1801 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2010 | 26375 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2019 | 2863 | 0.030 |
Why?
|
Blood Pressure | 3 | 2018 | 8540 | 0.030 |
Why?
|
Transplantation, Homologous | 1 | 2002 | 4833 | 0.030 |
Why?
|
Hepatitis C | 1 | 2003 | 1594 | 0.030 |
Why?
|
RNA | 1 | 2023 | 2718 | 0.030 |
Why?
|
Glycolysis | 1 | 2017 | 837 | 0.030 |
Why?
|
Liver Cirrhosis | 1 | 2003 | 1960 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2018 | 1193 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2017 | 2473 | 0.030 |
Why?
|
Immunocompetence | 1 | 2012 | 138 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2017 | 1605 | 0.030 |
Why?
|
Up-Regulation | 2 | 2014 | 4146 | 0.020 |
Why?
|
Kynurenine | 1 | 2012 | 142 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 474 | 0.020 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2020 | 2568 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 478 | 0.020 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2013 | 505 | 0.020 |
Why?
|
Wound Healing | 1 | 2022 | 2808 | 0.020 |
Why?
|
Acute Kidney Injury | 1 | 2003 | 1942 | 0.020 |
Why?
|
Off-Label Use | 1 | 2012 | 185 | 0.020 |
Why?
|
Molecular Weight | 1 | 2013 | 2173 | 0.020 |
Why?
|
Molecular Sequence Annotation | 1 | 2013 | 527 | 0.020 |
Why?
|
Glutamine | 1 | 2013 | 577 | 0.020 |
Why?
|
Isoantigens | 1 | 2012 | 562 | 0.020 |
Why?
|
Autoantigens | 1 | 2014 | 890 | 0.020 |
Why?
|
Drug Synergism | 1 | 2014 | 1760 | 0.020 |
Why?
|
Remission, Spontaneous | 1 | 2010 | 384 | 0.020 |
Why?
|
Atherosclerosis | 1 | 2006 | 3433 | 0.020 |
Why?
|
Nonlinear Dynamics | 1 | 2012 | 493 | 0.020 |
Why?
|
Mice, Knockout | 2 | 2017 | 14486 | 0.020 |
Why?
|
Blotting, Western | 1 | 2017 | 5024 | 0.020 |
Why?
|
Reactive Oxygen Species | 1 | 2017 | 2149 | 0.020 |
Why?
|
Serum Albumin | 1 | 2012 | 677 | 0.020 |
Why?
|
STAT3 Transcription Factor | 1 | 2012 | 874 | 0.020 |
Why?
|
Arginine | 1 | 2012 | 932 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2020 | 4415 | 0.020 |
Why?
|
Macrophages | 1 | 2022 | 5799 | 0.020 |
Why?
|
Chronic Disease | 2 | 2012 | 9384 | 0.020 |
Why?
|
Pilot Projects | 2 | 2013 | 8740 | 0.020 |
Why?
|
Receptors, Virus | 1 | 2010 | 652 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4648 | 0.020 |
Why?
|
Th17 Cells | 1 | 2012 | 791 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2012 | 3435 | 0.020 |
Why?
|
Calcium | 1 | 2019 | 5794 | 0.020 |
Why?
|
Th2 Cells | 1 | 2011 | 1076 | 0.020 |
Why?
|
Epitopes | 1 | 2011 | 2526 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 2011 | 1854 | 0.010 |
Why?
|
Cause of Death | 1 | 2015 | 3720 | 0.010 |
Why?
|
Gene Expression Regulation | 2 | 2013 | 11930 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2012 | 6231 | 0.010 |
Why?
|
Chemokines | 1 | 2008 | 963 | 0.010 |
Why?
|
Blood Glucose | 1 | 2018 | 6429 | 0.010 |
Why?
|
Choledocholithiasis | 1 | 2003 | 50 | 0.010 |
Why?
|
Ganciclovir | 1 | 2003 | 256 | 0.010 |
Why?
|
Endothelial Cells | 1 | 2016 | 3589 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2019 | 59598 | 0.010 |
Why?
|
Liver Cirrhosis, Biliary | 1 | 2003 | 108 | 0.010 |
Why?
|
Acute Disease | 2 | 2003 | 7241 | 0.010 |
Why?
|
Homocysteine | 1 | 2006 | 637 | 0.010 |
Why?
|
Gallbladder Diseases | 1 | 2003 | 139 | 0.010 |
Why?
|
Survivors | 1 | 2012 | 2381 | 0.010 |
Why?
|
Linear Models | 1 | 2012 | 5884 | 0.010 |
Why?
|
Phosphorylation | 1 | 2013 | 8314 | 0.010 |
Why?
|
Sulfonylurea Compounds | 1 | 2003 | 220 | 0.010 |
Why?
|
C-Peptide | 1 | 2003 | 443 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2012 | 6517 | 0.010 |
Why?
|
Immunoglobulin G | 2 | 2003 | 4564 | 0.010 |
Why?
|
Physical Fitness | 1 | 2006 | 744 | 0.010 |
Why?
|
Severity of Illness Index | 2 | 2012 | 15944 | 0.010 |
Why?
|
Adolescent | 4 | 2013 | 89155 | 0.010 |
Why?
|
Genotype | 1 | 2013 | 13042 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2017 | 20218 | 0.010 |
Why?
|
Immunoglobulin M | 1 | 2003 | 1527 | 0.010 |
Why?
|
Postoperative Period | 1 | 2003 | 1826 | 0.010 |
Why?
|
Antihypertensive Agents | 1 | 2008 | 2029 | 0.010 |
Why?
|
Emergencies | 1 | 2003 | 1224 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2012 | 8052 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2011 | 12797 | 0.010 |
Why?
|
Comorbidity | 1 | 2011 | 10590 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2011 | 10470 | 0.010 |
Why?
|
Liver Diseases | 1 | 2003 | 1305 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2013 | 12795 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2003 | 6314 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2012 | 18344 | 0.010 |
Why?
|
Graft Survival | 1 | 2003 | 3887 | 0.010 |
Why?
|
Treatment Outcome | 3 | 2003 | 65364 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 2003 | 3216 | 0.010 |
Why?
|
Age Factors | 1 | 2008 | 18407 | 0.010 |
Why?
|
Antiviral Agents | 1 | 2003 | 3073 | 0.010 |
Why?
|
Recurrence | 1 | 2003 | 8507 | 0.010 |
Why?
|
Survival Analysis | 1 | 2003 | 10098 | 0.010 |
Why?
|
Hypoglycemic Agents | 1 | 2003 | 3108 | 0.010 |
Why?
|
Exercise | 1 | 2006 | 5955 | 0.000 |
Why?
|
Insulin | 1 | 2003 | 6606 | 0.000 |
Why?
|
Inflammation | 1 | 2008 | 10871 | 0.000 |
Why?
|
Antibodies, Monoclonal | 1 | 2003 | 9252 | 0.000 |
Why?
|
Child | 1 | 2013 | 80906 | 0.000 |
Why?
|